Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BOLD

Boundless Bio Inc.

Apr 23 • 04:00PM ET

10.66

Dollar change +0.65
Percentage change 6.49	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	46.38%	Shs Outstand	22.24M	Perf Week	0.95%
Market Cap	237.08M	Forward P/E	-	EPS next Y	-3.83	Insider Trans	9.70%	Shs Float	11.93M	Perf Month	-
Income	-	PEG	-	EPS next Q	-0.64	Inst Own	12.31%	Short Float	0.00%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	92.13%	Inst Trans	-	Short Ratio	0.00	Perf Half Y	-
Book/sh	-5.71	P/B	-	EPS next Y	-19.84%	ROA	-	Short Interest	0.00M	Perf Year	-
Cash/sh	5.43	P/C	1.96	EPS next 5Y	13.20%	ROE	-	52W Range	9.83 - 15.24	Perf YTD	-25.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-30.05%	Beta	-
Dividend TTM	-	Quick Ratio	13.27	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.44%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	13.27	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	10.08% -
Employees	72	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	23.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.35	Prev Close	10.01
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	316.72K	Price	10.66
SMA20	-11.33%	SMA50	-11.33%	SMA200	-11.33%	Trades		Volume	111,682	Change	6.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 02 '24	Buy	16.00	312,500	5,000,000	1,884,787	Apr 04 04:15 PM
ARCH Venture Fund IX, L.P.	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
CRANDELL KEITH	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
Burow Kristina	Director	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLD

Boundless Bio Inc.

Upgrade your FINVIZ experience